|Surgical treatment in Strangulated Inguinal Hernia in Newborns and Infants
AJ Khamraev, IM Karimov, AF Shamsiev
January-March 2018, 3(1):8-10
To date, the gerontology pediatric treatment choice problem inguinal hernias in children continues to occupy a leading position in surgical operation, since it is one of the most common diseases in infants, especially up to 3 years. In cases where the hernia reduce a spontaneous, against the conservative child left the event in a hospital where the necessary investigations were carried out for further surgical treatment to "routinely". On the basis of its own historical and clinical data, analyzed the results of treatment of strangulated inguinal hernias in 50 newborns and infants. To prevent complications strangulated inguinal hernias in infants and premature babies play an important role technical aspects. The indications for the establishment of the Roux plastics in strangulated inguinal hernias in infants and babies were large hernia and prematurity. Postoperative complications have arisen in the form hematoma in 5.4% of cases and scrotal edema - 10%. The high position of the testis was observed in 2.5% of children. Management of pediatric surgeon strangulated inguinal hernias in infants and infants depends on timely diagnosis and timing of onset of the disease.
| ||106 ||8 ||- |
|Effect of simvastatin on the transforming growth factor β1, fibroscan scores, and aspartate transaminase to platelet index ratio patients with Liver Cirrhosis
P Kusnanto, NA Prabowo, P Bambang
January-March 2018, 3(1):1-7
Background: Cirrhosis of the liver is the liver disorder marked fibrosis and abnormal liver architecture. Treatment of liver cirrhosis, among others, is to reduce fibrogenesis. Simvastatin as an anti-fibrotic among others, by a mechanism reduce the activity of hepatic stellate cell of the liver, reduce cell proliferation liver stelat, increases the production of nitric oxide and decrease vascular resistance in the liver cirrhosis.
Aim: This research to determine effect of simvastatin on the transforming growth factor β1, fibroscan scores, and aspartate transaminase to platelet index ratio patients with liver cirrhosis.
Methods: This study is a randomized experiment, a sample of 30 people, divided into a control group given a placebo and the treatment given simvastatin 20 mg / day orally for 4 weeks. Before and after treatment measured levels of TGF β1, FibroScan score, and a score of APRI. Statistical analysis using SPSS 22 for windows. Two different test mean using parametric tests (independent t test, paired t test) and if the data is normally distributed variable or non-parametric tests (Mann-Whitney / Wilcoxon Signed Rank Test). P significant if p <0.05.
Results: The results showed that the administration of simvastatin 20 mg for 4 weeks will reduce levels TGF β1 (20,98+7,80 μg/dl pretreatment, 16,20+5,50μg/dl post treatment; p=0,013), reduce fibroscan scores (22,29+14,65 kpa pretreatment, 13,61+4,02 kpa post treatment; p=0,049) and reduce APRI scores (40,13+41,28 pretreatment, 23,41+17,61 post treatment; p=0,002).
Conclusion: This study demonstrated that administration Simvastatin will be reduced levels of the transforming growth factor β1, fibroscan scores, and aspartate transaminase to platelet index ratio patients with liver cirrhosis.
| ||76 ||22 ||- |